Current Report · Items 8.01, 9.01 · 8-K

Anebulo Pharmaceuticals, Inc.

Other Events

Filed Jan 29, 2026Accepted Jan 29, 2026, 4:15 AM ESTCIK 1815974Accession 0001493152-26-004154

Company context

Anebulo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing novel solutions for people suffering from cannabis-induced toxicity. Its lead product candidate, selonabant, has completed a Phase 2 clinical trial evaluating its utility in blocking and reversing the negative effects of acute cannabinoid intoxication in healthy adults challenged with oral THC. Rather than proceeding directly with Phase 3 studies of oral selonabant in adults with ACI, the Company is prioritizing the advancement of a selonabant IV formulation as a potential treatment for pediatric patients with acute cannabis-induced toxicity, which it believes offers the potential for a faster timeline to approval relative to the adult oral product. Anebulo has scaled up the intravenous formulation for initial clinical safety studies, and initiated a Phase 1 SAD study of IV selonabant in September 2025. Selonabant is a competitive antagonist at the human CB1 receptor. For further information about Anebulo, please visit www.anebulo.com.

Current securities

ANEBOTC · EQUITY · Current

Historical securities (1)

ANEBNASDAQ · EQUITY · Historical · closed Aug 21, 2026

Recent company filings

Disclosure sections

Items 8.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 8.01Item 8.01 - Other Events

Item 8.01 Other Events. Tender Offer Final Results On January 29, 2026, Anebulo Pharmaceuticals, Inc., a Delaware corporation (“Anebulo” or the “Company”), issued a press release announcing the final results of its previously announced tender offer to purchase for cash up to 300,000 shares of its common stock, par value $0.001 per share (“Common Stock”), at a purchase price of $3.50 per share, to the seller in cash, less any applicable withholding taxes and without interest, which tender offer expired one minute after 11:59 p.m., New York City time, on January 26, 2026. Based on the final count by Broadridge Corporate Issuer Solutions, LLC, the depositary for the tender offer, a total of 4,907,881 shares of Common Stock were properly tendered and not properly withdrawn. The tender offer was oversubscribed. In accordance with the terms and conditions of the tender offer and based on the final count by the depositary, Anebulo accepted for payment an aggregate of 300,000 shares, including 134,306 “odd lots,” of its Common Stock at a purchase price of $3.50 per share, for an aggregate cost of approximately $1.05 million, excluding fees and expenses relating to the tender offer. Anebulo accepted the shares on a pro rata basis, except for tenders of “odd lots,” which were accepted in full. Anebulo has been informed by the depositary that the final proration factor for the tender offer was 3.47392%. The shares accepted for payment represent approximately 0.73% of the shares that were outstanding as of January 26, 2026. Payment for the shares accepted for purchase pursuant to the tender offer, and the return of all other shares tendered and not purchased, will occur promptly. Payment for shares will be made in cash, without interest. A copy of the press release issued by the Company is filed as Exhibit 99.1 hereto and is incorporated by reference herein. Important Additional Information This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any shares of Common Stock or any other securities.

Filed exhibits (1)

EX-99.1 (by filename) ex99-1.htm

EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Anebulo Pharmaceuticals Announces Final Results of Tender Offer AUSTIN, Texas (January 29, 2026) - Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced the final results of its voluntary self-tender offer to purchase 300,000 shares of its common stock, par value $0.001 per share (“Common Stock”), which expired one minute after 11:59 p.m., New York City time, on January 26, 2026. Based on the final count by Broadridge Corporate Issuer Solutions, LLC, the depositary for the tender offer, a total of 4,907,881 shares of Common Stock were properly tendered and not properly withdrawn. The tender offer was oversubscribed. In accordance with the terms and conditions of the tender offer and based on the final count by the depositary, Anebulo accepted for payment an aggregate of 300,000 shares of its Common Stock, including 134,306 “odd lots,” at a purchase price of $3.50 per share, for an aggregate cost of approximately $1.05 million, excluding fees and expenses relating to t…

Open exhibit ↗